NCT00784966

Islet After Kidney Transplant for Type 1 Diabetes

Pancreatic Islet Transplantation in Patients With Type 1 Diabetes Mellitus

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.

Conditions

• Type 1 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	etanercept	Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
DRUG	etanercept	Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.

Timeline

• Start date: 2011-08-01
• Primary completion: 2015-09-01
• Completion: 2017-09-01
• First posted: 2008-11-05
• Last updated: 2014-09-16

Locations

1 site across 1 country: United States